Table 1. Correlation between the expression of THBS4 in tumor stromal cells and clinicopathologic features in 584 patients with gastric carcinoma.

	THBS4
	High (n = 223, 38.2%)	Low (n = 361, 61.8%)	p value
Age (year-old)
< 65	105 (47.1%)	151 (41.8%)
≥ 65	118 (52.9%)	210 (58.2%)	0.247
Gender
Female	97 (43.5%)	162 (44.9%)
Male	126 (56.5%)	199 (55.1%)	0.810
αSMA expression
High	139 (62.3%)	136 (37.7%)
Low	84 (37.7%)	225 (62.3%)	<0.001
Macroscopic type
type 4	52 (23.3%)	9 (2.5%)
Other types	171 (76.7%)	352 (97.5%)	<0.001
Tumor diameter
< 50	103 (46.4%)	250 (69.3%)
≥ 50	120 (53.6%)	111 (30.7%)	<0.001
Microscopic type
Differentiated	81 (36.3%)	205 (56.8%)
Undifferentiated	142 (63.7%)	156 (43.2%)	<0.001
Depth of tumor invasion
T1-2	73 (32.7%)	264 (73.1%)
T3-4	150 (67.3%)	97 (26.9%)	<0.001
Lymph node metastasis
N0	83 (37.2%)	246 (68.1%)
N1-3	140 (62.8%)	115 (31.9%)	<0.001
Lymphatic invasion
Absent	56 (25.1%)	204 (56.5%)
Present	167 (74.9%)	157 (43.5%)	<0.001
Venous invasion
Absent	176 (84.2%)	305 (79.1%)
Present	47 (15.8%)	56 (20.9%)	0.109
Ascites cytology
Negative	174 (78.0%)	346 (95.8%)
Positive	49 (22.0%)	15 (4.2%)	<0.001
Peritoneal metastasis
Absent	200 (89.7%)	349 (96.7%)
Present	23 (10.3%)	12 (3.3%)	0.001
Hepatic metastasis
Negative	216 (96.9%)	354 (98.1%)
Positive	7 (3.1%)	7 (1.9%)	0.409
pStage
I, II	99 (44.4%)	285 (78.9%)
III, IV	124 (55.6%)	76 (21.1%)	<0.001